• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed—mutation rate of the marker higher than expected-Reference-Cited by-同舟云学术

• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed—mutation rate of the marker higher than expected

Published:2018-06-11 Issue:4 Volume:50 Page:160-166
ISSN:1682-8631
Container-title:European Surgery
language:en
Short-container-title:Eur Surg

Author:

Kappel-Latif Sonja^ORCID, ,Zacherl Johannes,Hejna Michael,Westerhoff Maria,Tamandl Dietmar,Ba-Ssalamah Ahmed,Mittlböck Martina,Wolf Brigitte,Wrba Friedrich,Kührer Irene,Pluschnig Ursula,Schoppmann Sebastian F.,Függer Reinhold,Zwrtek Ronald,Glaser Karl,Karner Josef,Längle Friedrich,Wenzl Etienne,Roka Rudolf,Öfner Dietmar,Tschmelitsch Jörg,Hold Michael,Keil Felix,Gnant Michael,Kandioler Daniela

Funder

Medical University of Vienna

Publisher

Springer Science and Business Media LLC

Subject

Surgery

Link

http://link.springer.com/article/10.1007/s10353-018-0527-z/fulltext.html

Reference20 articles.

1. Zacherl J, Neumayer C, Langer FB. Esophageal cancer: International guidelines in interdisciplinay diagnosis and treatment. Eur Surg. 2006;38(2):79–88.

2. Brenner B, Ilson DH, Minsky BD. Treatment of localized esophageal cancer. Semin Oncol. 2004;31(4):554–65.

3. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2003;185(6):538–43.